These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 21515838)
21. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA; Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629 [TBL] [Abstract][Full Text] [Related]
22. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. Serebruany VL; Malinin AI; Pokov A; Barsness G; Hanley DF Am Heart J; 2008 Jan; 155(1):93.e1-7. PubMed ID: 18082496 [TBL] [Abstract][Full Text] [Related]
23. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Sacco M; Pellegrini F; Roncaglioni MC; Avanzini F; Tognoni G; Nicolucci A; Diabetes Care; 2003 Dec; 26(12):3264-72. PubMed ID: 14633812 [TBL] [Abstract][Full Text] [Related]
24. Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus. Ariturk Z; Islamoglu Y; Gündüz E; Yavuz C; Cil H; Tekbas E; Soydinc S; Kaya H; Elbey MA Eur Rev Med Pharmacol Sci; 2012 May; 16(5):617-21. PubMed ID: 22774402 [TBL] [Abstract][Full Text] [Related]
25. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. Abdin AA; Baalash AA; Hamooda HE J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014 [TBL] [Abstract][Full Text] [Related]
26. Antibodies to GAD in Japanese patients classified as Type 2 diabetes at diagnosis. High titre of GAD Ab is a predictive marker for early insulin treatment--report of west Japan (Kyushu, Yamaguchi, Osaka) study for GAD Ab(+) diabetes. Takino H; Yamasaki H; Abiru N; Sera Y; Abe T; Kawasaki E; Yamaguchi Y; Eguchi K; Kanazawa Y; Nagataki S Diabet Med; 2002 Sep; 19(9):730-4. PubMed ID: 12207808 [TBL] [Abstract][Full Text] [Related]
27. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Verma S; Poulter NR; Bhatt DL; Bain SC; Buse JB; Leiter LA; Nauck MA; Pratley RE; Zinman B; Ørsted DD; Monk Fries T; Rasmussen S; Marso SP Circulation; 2018 Dec; 138(25):2884-2894. PubMed ID: 30566004 [TBL] [Abstract][Full Text] [Related]
28. Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study. Kuo S; Yang CT; Wu JS; Ou HT Diabetes Obes Metab; 2019 Feb; 21(2):312-320. PubMed ID: 30187666 [TBL] [Abstract][Full Text] [Related]
29. Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment. Saleh N; Petursson P; Lagerqvist B; Skúladóttir H; Svensson A; Eliasson B; Gudbjörnsdottir S; Eeg-Olofsson K; Norhammar A Diabetologia; 2012 Aug; 55(8):2109-17. PubMed ID: 22566103 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of combination therapy with insulin and oral hypoglycemic agents in patients with type II diabetes during a 1-year period. Mozersky RP; Patel H; Bahl VK; Bahl S; Mook W J Am Osteopath Assoc; 1996 Jun; 96(6):346-51. PubMed ID: 8690621 [TBL] [Abstract][Full Text] [Related]
31. Predictive factors for the efficacy of switch to oral hypoglycemic agents in Japanese type 2 diabetic patients with intensive insulin therapy temporarily introduced. Yamamoto Y; Takahara M; Yasuda T; Katakami N; Matsuoka TA; Kaneto H; Shimomura I Endocr J; 2014; 61(9):911-9. PubMed ID: 25048394 [TBL] [Abstract][Full Text] [Related]
32. Does aspirin use reduce cardiovascular risk in diabetes? Colwell JA Nat Rev Endocrinol; 2009 Apr; 5(4):188-90. PubMed ID: 19352314 [TBL] [Abstract][Full Text] [Related]
33. [Series, clinical study from Japan and its reflections; Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial]. Ogawa H Nihon Naika Gakkai Zasshi; 2011 Jan; 100(1):218-23. PubMed ID: 21387659 [No Abstract] [Full Text] [Related]
34. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents. Ajjan RA; Grant PJ Diab Vasc Dis Res; 2006 Dec; 3(3):147-58. PubMed ID: 17160909 [TBL] [Abstract][Full Text] [Related]
35. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989 [TBL] [Abstract][Full Text] [Related]
36. Effects of fasting blood glucose, diabetes treatment, blood pressure and anti-hypertension treatment on cardiovascular disease incidence: a 30-year follow-up study of 740 incident patients with Type 2 diabetes. Jansson SP; Andersson DK; Svärdsudd K Diabet Med; 2013 Mar; 30(3):349-57. PubMed ID: 23278364 [TBL] [Abstract][Full Text] [Related]
37. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Genuth S Ann Intern Med; 1996 Jan; 124(1 Pt 2):104-9. PubMed ID: 8554200 [TBL] [Abstract][Full Text] [Related]
38. A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. Pradhan AD; Cook NR; Manson JE; Ridker PM; Buring JE Diabetes Care; 2009 Jan; 32(1):3-8. PubMed ID: 18835953 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112 [TBL] [Abstract][Full Text] [Related]
40. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes]. Machoy M Ann Acad Med Stetin; 2004; 50(2):29-39. PubMed ID: 16529163 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]